Human Immunodeficiency Virus Therapeutics Market Report 2026

Human Immunodeficiency Virus Therapeutics Market Overview

• Human Immunodeficiency Virus Therapeutics market size has reached to $14.9 billion in 2025 • Expected to grow to $19.4 billion in 2030 at a compound annual growth rate (CAGR) of 5.4% • Growth Driver: Increase In Unprotected Sexual Practices Fueling The Market Due To Limited Access To Contraception And Lack Of Comprehensive Sex Education • Market Trend: Long-Acting Injectable Prevention Breakthroughs Transforming HIV Care Accessibility And Adherence Worldwide • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Human Immunodeficiency Virus Therapeutics Market?

Human immunodeficiency virus (HIV) therapeutics refer to medications and treatment strategies designed to manage and suppress HIV infection, primarily through antiretroviral therapy (ART). These therapeutics help reduce viral load, prevent disease progression to AIDS, and improve the quality of life for individuals living with HIV. The main drug types of human immunodeficiency virus therapeutics are branded drugs and generic drugs. Branded drugs are patented medicines developed and sold under a unique name, undergoing rigorous research and clinical trials to ensure safety and effectiveness. The drug classes include nucleoside-analog reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), entry and fusion inhibitors, protease inhibitors (PIs), integrase inhibitors, and coreceptor antagonists. These drugs are distributed through hospital pharmacies, online pharmacies, and retail pharmacies and are used by end users such as hospitals, clinics, and specialty centers.

What Is The Human Immunodeficiency Virus Therapeutics Market Growth Forecast?

The human immunodeficiency virus therapeutics market size is expected to see strong growth in the next few years. It will grow to $19.4 billion in 2030 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to rising demand for long-acting hiv therapeutics, increasing focus on personalized hiv treatment regimens, expansion of access to hiv treatment in low and middle income countries, growing investments in next-generation antiretroviral drugs, increasing emphasis on lifelong hiv disease management. Major trends in the forecast period include increasing adoption of combination antiretroviral therapies, rising shift toward long-acting injectable hiv treatments, growing focus on early and sustained viral suppression, expansion of generic antiretroviral drug availability, increasing emphasis on treatment adherence and simplified regimens.

Global Human Immunodeficiency Virus Therapeutics Market Segmentation

1) By Drug Type: Branded Drugs, Generic Drugs 2) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies 3) By End-user: Hospitals And Clinics, Specialty Centers Subsegments: 1) By Branded Drugs: Biktarvy, Triumeq, Genvoya, Juluca, Dovato, Isentress, Prezista 2) By Generic Drugs: Tenofovir Disoproxil Fumarate (TDF), Lamivudine, Efavirenz, Zidovudine, Nevirapine, Abacavir, Ritonavir

What Is The Driver Of The Human Immunodeficiency Virus Therapeutics Market?

The growing prevalence of unprotected sexual practices is expected to propel the growth of the human immunodeficiency virus therapeutics market going forward. Unprotected sexual practices refer to sexual activities without barrier protection, increasing the risk of sexually transmitted infections (STIs) and unintended pregnancies. Lack of comprehensive sex education leads to limited awareness about safe practices, which increases risky behavior among youth. Human immunodeficiency virus therapeutics help reduce the risk of HIV transmission from unprotected sexual practices by suppressing viral load to undetectable levels, preventing further spread of the infection. For instance, in November 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, in a 2023 survey of U.S. high school students, 32% reported having had sexual intercourse at least once, and 48% stated that they did not use a condom during their most recent sexual encounter. Therefore, the growing prevalence of unprotected sexual practices is driving the growth of the human immunodeficiency virus therapeutics industry.

Key Players In The Global Human Immunodeficiency Virus Therapeutics Market

Major companies operating in the human immunodeficiency virus therapeutics market are Gilead Sciences Inc., GlaxoSmithKline plc, Merck & Co. Inc., AbbVie Inc., Johnson & Johnson, Bristol Myers Squibb Company, Pfizer Inc., F Hoffmann La Roche Ltd., Sanofi SA, Novartis International AG, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Cipla Limited, Aurobindo Pharma Limited, Hetero Labs Limited, Viatris Inc., Sun Pharmaceutical Industries Ltd., Lupin Limited, Dr Reddy's Laboratories Ltd., Mylan N.V.

Global Human Immunodeficiency Virus Therapeutics Market Trends and Insights

Major companies operating in the Human Immunodeficiency Virus Therapeutics market are focusing on developing long-acting, highly effective prevention and treatment options, expanding access through supportive reimbursement programs, and advancing innovative clinical strategies to improve adherence and reduce new HIV infections. For instance, in June 2025, Gilead Sciences, a US-based healthcare company, received FDA approval for Yeztugo (lenacapavir), the first and only twice-yearly injectable PrEP option, marking a major advancement in HIV prevention. Backed by Phase 3 PURPOSE 1 and PURPOSE 2 data, the drug showed exceptional efficacy, with ≥99.9% of participants remaining HIV-negative. The long-acting injection aims to overcome barriers such as adherence challenges, stigma, and low awareness that limit current PrEP use. Yeztugo’s approval offers a promising tool to help reduce new HIV infections across diverse populations. Gilead is also implementing broad access measures, including insurance partnerships, co-pay support for eligible patients, and free access for uninsured individuals through assistance programs.

What Are Latest Mergers And Acquisitions In The Human Immunodeficiency Virus Therapeutics Market?

In July 2025, Future Pak, a US-based contract development and manufacturing organization (CDMO), acquired Theratechnologies Inc. for up to $254 million. With this acquisition, Future Pak aims to deepen its position in the HIV therapeutics market by integrating Theratechnologies’ marketed HIV drugs including Trogarzo and Egrifta and leveraging their expertise in commercialization to drive further growth. Theratechnologies, headquartered in Canada, is a biopharmaceutical company known for its HIV focused product portfolio, including its monoclonal antibody Trogarzo (ibalizumab) and HIV-associated lipodystrophy treatment Egrifta (tesamorelin)

Regional Outlook

North America was the largest region in the human immunodeficiency virus therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Human Immunodeficiency Virus Therapeutics Market?

The human immunodeficiency virus therapeutics market consists of revenues earned by entities by providing services such as telehealth and remote patient monitoring, patient support and case management services, clinical trials and research services, and HIV testing and diagnosis services. The market value includes the value of related goods sold by the service provider or included within the service offering. The human immunodeficiency virus therapeutics market also includes sales of antiretroviral drugs (ARVs), pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP), and immune system boosters. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Human Immunodeficiency Virus Therapeutics Market Report 2026?

The human immunodeficiency virus therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the human immunodeficiency virus therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.